New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
08:18 EDTROSGRosetta Genomics provides product pipeline update
Rosetta Genomics announces details regarding the company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics. Kenneth A. Berlin, president and CEO of Rosetta Genomics stated, "Rosetta Genomics continues to set the pace in developing and commercializing microRNA-based technologies. We have the most validated microRNA biomarker platform with approximately 50 peer-reviewed publications relating to our platform and have recently rejuvenated our research and development efforts to leverage this leading and versatile platform. We are moving forward on a variety of important projects to provide clinicians with better tools to improve patients' lives in a number of areas of unmet medical need with an aim to commercialize one new assay per year commencing in 2015. Building upon the company's four current commercial diagnostic assays, Rosetta is advancing several new diagnostic assays starting with our lead assay for the differential diagnosis of thyroid neoplasia. In addition, we are evaluating several assays for other cancers as well as assays for non-invasive diagnosis of chronic kidney rejection; the early diagnosis and risk stratification of heart failure patients; and the early diagnosis and differentiation of Alzheimer's disease."
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:08 EDTROSGRosetta Genomics announces commercial launch of OncoGxOne
Rosetta Genomics announces the commercial launch of OncoGxOne, Admera Health’s next-generation sequencing panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. OncoGxOne was recently approved as a Laboratory Developed Test and is the fifth new product introduced by Rosetta Genomics in 2015.
May 26, 2015
09:03 EDTROSGRosetta announces selection of first pilot project grant under MCC alliance
Rosetta Genomics (ROSG) announces the selection of the first project grant under its strategic alliance with Moffitt Cancer Center. The funded project is titled, “miRNAs as Determinants and Predictors of Ibrutinib Resistance in Mantle Cell Lymphoma.” The project will be led by Jianguo Tao, M.D., Ph.D., a renowned hematopathologist and physician-scientist at the Molecular and Chemical Biology Program at Moffitt, and Bijal Shah, M.D., an oncologist in the Experimental Therapeutic Program at Moffitt. MCL is an aggressive B-cell lymphoma. Ibrutinib, a blockbuster pharmaceutical marketed by Pharmacyclics (PCYC) under the brand name of IMBRUVICA, is a novel Bruton's tyrosine kinase inhibitor that received U.S. Food and Drug Administration approval for the treatment of MCL in 2014, with high response rates reported in patients with MCL. However, many MCL patients who initially show a partial or complete response to ibrutinib, eventually develop ibrutinib-acquired drug resistance accompanied by fulminant progression and accelerated mortality. Studies conducted by Drs. Tao and Shah have suggested that microRNAs play a role in the development of resistance to ibrutinib. The goal of this funded project is to further explore the role and underlying molecular mechanism of microRNAs in ibrutinib resistance in MCL, for development of microRNA-based predictive biomarkers for ibrutinib therapy, as well as for a rational design to overcome drug resistance.
May 14, 2015
08:50 EDTROSGRosetta Genomics launches two assays for bladder cancer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use